Tvardi Therapeutics advances TTI-109 toward IBD IND after FDA feedback
TVRD•Tvardi Therapeutics plans to submit an IND for its oral STAT3 inhibitor TTI-109 in inflammatory bowel disease in 2027. The FDA said nonclinical studies support a Phase 2 trial and provided guidance on dosing and study design; the trial remains subject to FDA review.




